Genomics Essentials in Hematologic Malignancies
Genomics is central to the diagnosis, risk stratification and prognosis, disease monitoring, and therapeutic decision-making in hematologic malignancies. Clinicians managing patients with hematologic malignancies are faced with making decisions about which tests to order and when, interpreting test results, and which therapies to select–including when to start, stop, adjust, or change.
This program will provide clinicians treating hematologic malignancies with a foundational understanding of genomics, expert insights on the current applications/practical strategies of genetic testing, and real-world patient case examples to demonstrate how to apply new knowledge of genomics to the optimal management of patients. Participate in GENOM, a free education program created in partnership by ASH, Leukemia and Lymphoma Society, and The France Foundation.
The GENOM program offers online learning modules for CME credit designed to help clinicians identify genomic principles, applications, technologies, and terminology relating to biomarker development. The course also includes an audio component available through ASH’s new podcast, “HemeTalks: Conversations in Hematology Education.”
GENOM Foundations Microlearning Modules
Begin your education with an interactive series exploring the core principles related to genomics in hematologic malignancies. Are you confident with the basic principles of genomics? Learn more and develop a solid foundation.
- Clinical Applications: Overview of Genomic Tests and Their Use in Guiding Clinical Decisions
- Dr. Rafael Fonseca provides an interactive overview biomarkers and their use in clinical decision-making
- Patient Points: Explaining the Importance and Implications of Testing
- Dr. Neha Mehta-Shah provides strategies to talk to patients about genomic tests and their implications
- Glossary of Terms
- A downloadable PDF document that can be used as a resource for the various types of genomic testing
Applications Adaptive Learning Modules
These disease-specific modules explore relevant biomarkers, available tests and therapies, patient communication strategies, and emerging research. Dive deeper into AML, MDS, and Lymphoma topics with this engaging learning tool designed to give you a deeper learning experience. Are you ready to take the next step to enhance your knowledge?
This series of six, 15-minute podcasts feature faculty from academic and community oncology settings discussing disease-specific experiences with genomic testing, from test ordering to therapeutic decision-making steps. Topics include AML, ALL, CLL, MDS/CHIP, Myeloma, and Lymphoma.
Who Should Participate?
This activity is intended for hematologists, hematologists/oncologists, medical oncologists, nurses, and physician assistants and nurse practitioners who are caring for patients with blood cancers.
- Jennifer Brown, MD, PhD (Steering Committee Chair), Dana-Farber Cancer Institute, Harvard Medical School
- Rafael Fonseca, MD, Mayo Clinic Comprehensive Cancer Center
- Neha Mehta-Shah, MD, MSCI, Washington University in St. Louis School of Medicine
- Alice Mims, MD, The Ohio State University Comprehensive Cancer Center
- Nina Fragale, NP, Washington University in St. Louis School of Medicine